Analysis of sialic acid levels in Chinese intravenous immunoglobulins by high-performance liquid chromatography with fluorescence detection

Study on the Treatment of ITP Mice with IVIG Sourced from Distinct Sex-Special Plasma (DSP-IVIG)

Intravenous immunoglobulin (IVIG) is a first-line drug prepared from human plasma for the treatment of autoimmune diseases (AIDs), especially immune thrombocytopenia (ITP). Significant differences exist in protein types and expression levels between male and female plasma, and the prevalence of autoimmune diseases varies between sexes. The present study seeks to explore potential variations in IVIG sourced from distinct sex-specific plasma (DSP-IVIG), including IVIG sourced from female plasma (F-IVIG), IVIG sourced from male plasma (M-IVIG), and IVIG sourced from a blend of male and female plasma (Mix-IVIG). To address this question, we used an ITP mouse model and a monocyte-macrophage inflammation model treated with DSP IVIG. The analysis of proteomics in mice suggested that the pathogenesis and treatment of ITP may involve FcγRs mediated phagocytosis, apoptosis, Th17, cytokines, chemokines, and more. Key indicators, including the mouse spleen index, CD16+ macrophages, M1, M2, IL-6, IL-27, and IL-13, all indicated that the efficacy in improving ITP was highest for M-IVIG. Subsequent cell experiments revealed that M-IVIG exhibited a more potent ability to inhibit monocyte phagocytosis. It induced more necrotic M2 cells and fewer viable M2, resulting in weaker M2 phagocytosis. M-IVIG also demonstrated superiority in the downregulation of surface makers CD36, CD68, and CD16 on M1 macrophages, a weaker capacity to activate complement, and a stronger binding ability to FcγRs on the THP-1 surface. In summary, DSP-IVIG effectively mitigated inflammation in ITP mice and monocytes and macrophages. However, M-IVIG exhibited advantages in improving the spleen index, regulating the number and typing of M1 and M2 macrophages, and inhibiting macrophage-mediated inflammation compared to F-IVIG and Mix-IVIG.

In Situ Determination of Sialic Acid on Cell Surface with a pH-Regulated Polymer Enzyme Nanoreactor

Sialic acid (SA) is an important monosaccharide that is involved in incurable cancer immunotherapy. However, it is difficult to detect SA in situ using the existing strategy based on the SA-terminated glycopeptide extraction from the cell lysate. The countermeasures of the bottleneck caused by cell disruption and peptide extraction should be designed based on a "cell-surface attachment and controlled enzymolysis" protocol. Herein, a poly(styrene-co-maleic anhydride-acrylic acid-concanavalin A) (PSM-PAA-ConA) was synthesized and developed as a pH-regulated enzyme nanoreactor after being loaded with sialidase and myoglobin. The nanoreactor showed controllable biocatalysis induced by a cascade enzyme reaction and applied for the in situ detection of SA on a living cell surface. The addition of an acidic solution resulted in a decrease in the size of the nanoreactor and enhancement of its permeability, triggering an "on" state of the SA catalysis. Subsequent pH increase led to increased hydrophilicity of the nanoreactor, increasing its size and resulting in the catalytic "off" state. ConA assisted the cell-surface attachment of the enzyme reactor. Furthermore, SA on the surface of living cancer cells was successfully monitored by the pH-regulated enzyme nanoreactor, demonstrating the feasibility of high specificity in situ analysis for SA. This pH-induced catalytic efficiency control by the enzyme nanoreactor provides a potential platform for functional stimuli-responsive catalytic systems as well as a strategy for in situ analysis of biomolecules on the cell surface.